Becton, Dickinson and Company (NYSE:BDX) EVP Roland Goette Sells 2,438 Shares

Becton, Dickinson and Company (NYSE:BDX) EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Becton, Dickinson and Company Stock Up 1.0%

Shares of BDX stock traded up $1.73 during trading hours on Wednesday, hitting $183.14. 1,551,492 shares of the company’s stock traded hands, compared to its average volume of 2,694,387. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock’s fifty day simple moving average is $156.55 and its two-hundred day simple moving average is $161.69. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The stock has a market cap of $50.46 billion, a price-to-earnings ratio of 55.16, a PEG ratio of 12.66 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently modified their holdings of the company. Larson Financial Group LLC increased its position in shares of Becton, Dickinson and Company by 1.7% during the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after purchasing an additional 53 shares during the last quarter. Camelot Portfolios LLC grew its position in Becton, Dickinson and Company by 1.5% during the fourth quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock valued at $688,000 after acquiring an additional 54 shares during the last quarter. Atlantic Union Bankshares Corp grew its position in Becton, Dickinson and Company by 0.9% during the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after acquiring an additional 57 shares during the last quarter. PDS Planning Inc raised its stake in shares of Becton, Dickinson and Company by 3.6% during the fourth quarter. PDS Planning Inc now owns 1,678 shares of the medical instruments supplier’s stock worth $326,000 after acquiring an additional 58 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC lifted its holdings in shares of Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock worth $256,000 after acquiring an additional 60 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BDX. The Goldman Sachs Group dropped their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Royal Bank Of Canada boosted their price target on Becton, Dickinson and Company from $175.00 to $180.00 and gave the stock a “sector perform” rating in a research note on Friday, August 7th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research report on Monday, July 6th. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a report on Friday, August 7th. Finally, Bank of America lowered their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $185.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.